Gracell Biotechnologies Inc. (GRCL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Gracell Biotechnologies Inc. stock (GRCL) is currently trading at $10.25. Gracell Biotechnologies Inc. PS ratio (Price-to-Sales) is 732.21. Analyst consensus price target for GRCL is $10.58. WallStSmart rates GRCL as Sell.
- GRCL PE ratio analysis and historical PE chart
- GRCL PS ratio (Price-to-Sales) history and trend
- GRCL intrinsic value — DCF, Graham Number, EPV models
- GRCL stock price prediction 2025 2026 2027 2028 2029 2030
- GRCL fair value vs current price
- GRCL insider transactions and insider buying
- Is GRCL undervalued or overvalued?
- Gracell Biotechnologies Inc. financial analysis — revenue, earnings, cash flow
- GRCL Piotroski F-Score and Altman Z-Score
- GRCL analyst price target and Smart Rating
Gracell Biotechnologies Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Gracell Biotechnologies Inc. (GRCL) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Gracell Biotechnologies Inc. (GRCL) Key Strengths (1)
63.11% held by institutions, strong professional interest
Gracell Biotechnologies Inc. (GRCL) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 732.2x annual revenue
Premium pricing at 4.4x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Gracell Biotechnologies Inc. (GRCL) Detailed Analysis Report
Overall Assessment
This company scores 17/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (732.21), Price/Book (4.39) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -31.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -31.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GRCL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GRCL's Price-to-Sales ratio of 732.21x sits near its historical average of 732.21x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 732.21x set in Feb 2026, and 0% above its historical low of 732.21x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Gracell Biotechnologies Inc. (GRCL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Gracell Biotechnologies Inc. operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Gracell Biotechnologies Inc..
Bottom Line
Gracell Biotechnologies Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:23:44 AM
About Gracell Biotechnologies Inc.(GRCL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
China
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for cancer treatment in the People's Republic of China. The company is headquartered in Suzhou, China.